183 related articles for article (PubMed ID: 28854082)
1. Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
Tesar D; Luoma J; Wyatt EA; Shi C; Shatz W; Hass PE; Mathieu M; Yi L; Corn JE; Maass KF; Wang K; Dion MZ; Andersen N; Loyet KM; van Lookeren Campagne M; Rajagopal K; Dickmann L; Scheer JM; Kelley RF
MAbs; 2017; 9(8):1297-1305. PubMed ID: 28854082
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches.
Loyet KM; Hass PE; Sandoval WN; Morando A; Liu P; Shatz W; Dickmann L; Kenrick M; Good J; Davancaze T; Morimoto AM; Kelley RF; Scheer JM
Mol Pharm; 2019 Jan; 16(1):86-95. PubMed ID: 30444371
[TBL] [Abstract][Full Text] [Related]
3. Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
Koenig P; Lee CV; Sanowar S; Wu P; Stinson J; Harris SF; Fuh G
J Biol Chem; 2015 Sep; 290(36):21773-86. PubMed ID: 26088137
[TBL] [Abstract][Full Text] [Related]
4. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
[TBL] [Abstract][Full Text] [Related]
5. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
6. A general approach to antibody thermostabilization.
McConnell AD; Zhang X; Macomber JL; Chau B; Sheffer JC; Rahmanian S; Hare E; Spasojevic V; Horlick RA; King DJ; Bowers PM
MAbs; 2014; 6(5):1274-82. PubMed ID: 25517312
[TBL] [Abstract][Full Text] [Related]
7. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
8. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
9. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
Loyet KM; Good J; Davancaze T; Sturgeon L; Wang X; Yang J; Le KN; Wong M; Hass PE; van Lookeren Campagne M; Haughney PC; Morimoto A; Damico-Beyer LA; DeForge LE
J Pharmacol Exp Ther; 2014 Dec; 351(3):527-37. PubMed ID: 25232192
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic Acid-Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics.
Famili A; Crowell SR; Loyet KM; Mandikian D; Boswell CA; Cain D; Chan J; Comps-Agrar L; Kamath A; Rajagopal K
Bioconjug Chem; 2019 Nov; 30(11):2782-2789. PubMed ID: 31553572
[TBL] [Abstract][Full Text] [Related]
11. Fabs specific for 8-oxoguanine: control of DNA binding.
Bespalov IA; Bond JP; Purmal AA; Wallace SS; Melamede RJ
J Mol Biol; 1999 Nov; 293(5):1085-95. PubMed ID: 10547287
[TBL] [Abstract][Full Text] [Related]
12. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
13. Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology.
Kelley RF; Tesar DB; Wang Y; Agard NJ; Holder PG; Chan J; Comps-Agrar L; Horvath J; Horvath JD; Crowell SR
Mol Pharm; 2022 May; 19(5):1540-1547. PubMed ID: 35393854
[TBL] [Abstract][Full Text] [Related]
14. Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratope.
Lowe DC; Gerhardt S; Ward A; Hargreaves D; Anderson M; Ferraro F; Pauptit RA; Pattison DV; Buchanan C; Popovic B; Finch DK; Wilkinson T; Sleeman M; Vaughan TJ; Mallinder PR
J Mol Biol; 2011 Feb; 406(1):160-75. PubMed ID: 21167836
[TBL] [Abstract][Full Text] [Related]
15. Unravelling enhancement of antibody fragment stability - Role of format structure and cysteine modification.
Ma H; Ó'Fágáin C; O'Kennedy R
J Immunol Methods; 2019 Jan; 464():57-63. PubMed ID: 30468735
[TBL] [Abstract][Full Text] [Related]
16. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
[TBL] [Abstract][Full Text] [Related]
17. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
Rothe C; Urlinger S; Löhning C; Prassler J; Stark Y; Jäger U; Hubner B; Bardroff M; Pradel I; Boss M; Bittlingmaier R; Bataa T; Frisch C; Brocks B; Honegger A; Urban M
J Mol Biol; 2008 Feb; 376(4):1182-200. PubMed ID: 18191144
[TBL] [Abstract][Full Text] [Related]
18. Design and construction of synthetic phage-displayed Fab libraries.
Bostrom J; Fuh G
Methods Mol Biol; 2009; 562():17-35. PubMed ID: 19554284
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.
Adachi M; Kurihara Y; Nojima H; Takeda-Shitaka M; Kamiya K; Umeyama H
Protein Sci; 2003 Oct; 12(10):2125-31. PubMed ID: 14500870
[TBL] [Abstract][Full Text] [Related]
20. Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates.
Schoonbroodt S; Steukers M; Viswanathan M; Frans N; Timmermans M; Wehnert A; Nguyen M; Ladner RC; Hoet RM
J Immunol; 2008 Nov; 181(9):6213-21. PubMed ID: 18941211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
